Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study

• Status: Completed
• Trial end date: 2018-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this pilot study is to determine if intravenous tranexamic acid (TXA) is effective for reducing blood loss during high risk surgical procedures related to placenta previa and placenta accreta. TXA is currently used in other types of surgery for patients who are expected to have a large blood loss, such as orthopedic or open heart surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Collaborators: Central California Faculty Medical Group; University of California, San Francisco Fresno
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• English and Spanish speaking pregnant women

• Any order pregnancy (singleton, twin gestation, etc)

• Suspected accreta based on ultrasound or MRI imaging studies

• All women evaluated for placenta accreta and deemed to be high risk for this disease (≥40% risk), meaning women diagnosed with a placenta previa and greater than or equal to 2 prior c-sections

Exclusion Criteria:

• Women less than 18 years of age

• Women with a personal history of venous or arterial thrombosis (deep vein thrombosis, pulmonary embolism, myocardial infarction, or stroke

• Women with a personal history of a high risk clotting disorder, such as anti-phospholipid syndrome

• Women who do not have a good understanding of either English or Spanish will be excluded.

• Women with defective color vision (color-blindness)